We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > RubrYc

News List

RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc. firstwordpharma
August 26, 2021
RubrYc Therapeutics, Inc. ("RubrYc") and iBio, Inc. ("iBio", NYSEA: IBIO) announced today the closing of RubrYc's Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the research.
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics firstwordpharma
August 26, 2021
iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company" today announced that it has signed a definitive worldwide exclusive license agreement with RubrYc Therapeutics, Inc., ("RubrYc") for RTX-003, an immunotherapy candidate targeting regulatory T cells (Tregs).